<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122596">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769872</url>
  </required_header>
  <id_info>
    <org_study_id>KSC-MSCs-SPI</org_study_id>
    <nct_id>NCT01769872</nct_id>
  </id_info>
  <brief_title>Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury</brief_title>
  <official_title>Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>K-Stemcell Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>K-Stemcell Co Ltd</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the efficacy and safety of autologous
      transplantation of Adipose Tissue derived Mesenchymal stem cells (MSCs) in patient with
      spinal cord injury
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>ASIA (American Spinal Injury Association) scale</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord injury using Magnetic Resonance Imaging (MRI) at 3 and 6 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MEP/SSEP</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADL (activities of daily living)</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ODI (Oswestry Disability Questionnaire)</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the change of treated spinal cord before cell implantation and at 3 and 6 months post injection of MSCs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>32 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Spinal Cord Injury</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Adipose Tissue derived MSCs Transplantation</intervention_name>
    <description>Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who understand and sign the consent form for this study

          -  Age : 19-70

          -  Clinical diagnosis of spinal cord injury(American Spinal Injury Association[ASIA]
             Impairment Scale[AIS] grade A or B or C)

          -  Duration of injury : &gt; 3 month

        Exclusion Criteria:

          -  Subjects who must put on a respirator

          -  Subjects who had malignant tumor within 5 years

          -  Subjects with a infectious disease include HIV and hepatitis

          -  Subjects who injured brain or spinal cord before spinal cord injury

          -  Subjects with anemia or thrombocytopenia

          -  Subjects with angina pectoris, myocardial infarction, cardiomyopathy, occlusive
             disease, chronic renal failure, glomerular disease and chronic obstructive pulmonary
             disease

          -  Subjects with congenital or acquired immunodeficiency disorders

          -  Patients with clouded consciousness or speech disorder

          -  treat with cytotoxic medications(immunosuppressive drug, corticosteroid and cytotoxic
             drug) during clinical trials

          -  participating another clinical trials within 3 months

          -  other serious disease or disorder that could seriously affect ability to participate
             in the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tai-Hyoung Cho, M.D. &amp; Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Anam Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tai-Hyoung Cho, M.D. &amp; Ph.D.</last_name>
    <phone>82-10-3791-5338</phone>
    <email>choth2@korea.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tai-Hyoung Cho, M.D. &amp; Ph.D.</last_name>
      <phone>82-10-3791-5338</phone>
      <email>choth2@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Tai-Hyoung Cho, M.D. &amp; Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong-Hyuk Park, M.D. &amp; Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jang-Bo Lee, M.D. &amp; Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang-Heon Lee, M.D. &amp; Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 24, 2014</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
